Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

diaDexus licenses colorectal cancer test to Quest:

This article was originally published in Clinica

Executive Summary

diaDexus has licensed its proprietary genomics-based test for the detection of colorectal cancer to Quest Diagnostics. Quest has exclusive rights to develop and commercialise the test in its laboratories in the US and in certain international markets. South San Francisco, California-based diaDexus receives an upfront licensing fee and royalties. It also gets the rights to develop a test for certain markets in the future. The non-invasive test detects Reg-4, a protein that has been implicated in colorectal cancer and could be an important tool for early detection.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel